This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Institut Gustave Roussy. Active years: 2021.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2021
Title: Muhammad Zaeem Noman: Innovator in Cancer Treatment Assessment
Introduction
Muhammad Zaeem Noman is a notable inventor based in Thionville, France. He has made significant contributions to the field of cancer treatment through his innovative research. His work focuses on improving patient responses to targeted therapies, particularly in the context of PD-1/PDL-1 targeting drugs.
Latest Patents
Noman holds a patent for a method that assesses the response of patients to anti-PD-1/PDL-1 drugs. This invention is particularly relevant as it utilizes the status of the VHL gene (von Hippel-Lindau) to evaluate treatment efficacy. His patent represents a crucial advancement in personalized medicine, allowing for more tailored therapeutic approaches.
Career Highlights
Currently, Muhammad Zaeem Noman is affiliated with the Institut Gustave Roussy, a leading cancer research institution. His role there allows him to collaborate with other experts in the field and contribute to groundbreaking research aimed at improving cancer treatment outcomes.
Collaborations
Noman has worked alongside esteemed colleagues such as Salem Chouaib and Yosra Messai. These collaborations enhance the depth and impact of his research, fostering an environment of innovation and shared knowledge.
Conclusion
Muhammad Zaeem Noman's contributions to cancer treatment assessment through his patented method highlight his role as a key innovator in the medical field. His work not only advances scientific understanding but also has the potential to significantly improve patient care.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile